METHOD AND DEVICES FOR CELLULAR TRANSFER OF COMPOUNDS WITH AUGMENTED REALITY APPLICATION
The embodiments disclose a method, including suspending cannabinoid compound molecules and constituents in an aqueous solution, suspending Aloe Vera molecules and its constituents in an aqueous solution, wherein a combination of cannabinoid compound molecules and constituents and Aloe Vera molecules and its constituents may be used for suspending in an aqueous solution, encapsulating cannabinoid compound molecules and Aloe Vera molecules within a liposome in an aqueous solution, and blending the liposome encapsulated cannabinoid compound molecules and Aloe Vera molecules with other ingredients into a health beneficial product and delivery system for oral including sublingual ingestion and nasal spray and suppository insertion or topical application with a plurality of nano sensors by humans.
Delivery methods of medically beneficial products can a difference in whether a person will take the medically beneficial products. How the medically beneficial products ingredients are prepared affects the forms of delivery available to make the person consuming the medically beneficial products and can affect the potency and medical benefit efficacy.
In a following description, reference is made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration a specific example in which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.
General Overview:It should be noted that the descriptions that follow, for example, in terms of a method and devices for cellular transfer of compounds with augmented reality application is described for illustrative purposes and the underlying system can apply to any number and multiple types encapsulated molecules. In one embodiment of the present invention, the method and devices for cellular transfer of compounds with augmented reality application can be configured using a combination of CBD and Aloe Vera. The method and devices for cellular transfer of compounds with augmented reality application can be configured to include only encapsulated CBD molecules and can be configured to include only encapsulated Aloe Vera molecules using the present invention.
For example a treatment product that is targeted for persons suffering from depression may receive the benefits of CBD constituents that treat depression in a larger proportion than Aloe Vera constituents that treat depression based on studies on the efficacy of the different constituents for the treatment of depression of one embodiment. A device may be used for blending varying proportions of separately encapsulated cannabinoid compound molecules and Aloe Vera molecules for increasing health benefits of each for a specific purpose for a specific medical condition. The device may be coupled to a digital server, a plurality of databases and a computer.
The plurality of databases have recorded and stored data on varying proportional formulations of cannabinoid compound molecules and Aloe Vera molecules and their benefits for various medical conditions. The computer is used for querying the database for a specific medical condition and the cannabinoid and Aloe Vera constituent benefits. The digital server is used to instruct the blending device to blend with the liposome lipid in an aqueous solution proportional quantities of the various constituents using the varying proportional formulations of cannabinoid compound molecules and Aloe Vera molecules for blending a beneficial product and delivery system for a human to use for treatment of the specific medical condition of one embodiment.
Liposome Lipid Chemical Structure:Aloe vera is a rich source of over 200 naturally occurring nutrients which contain water soluble and fat soluble vitamins, minerals, enzymes, polysaccharides, phenolic compounds and organic acids. Its secondary metabolites have multiple properties such as anti-inflammatory, antibacterial, antioxidant, immune boosting, anticancer, antiaging, sunburn relief and antidiabetic potentials. Several traditional uses also have been reported such as burn injury, eczema, cosmetics, inflammation, and fever. Nine categories of phytochemical constituents of Aloe vera can be classified as, anthraquinones, inorganic compounds, amino acids, fatty acids, alkaloids, carbohydrates, enzymes, and vitamins along with other miscellaneous compounds.
Aloe vera contains 75 potentially active constituents: vitamins, enzymes, minerals, sugars, lignin, saponins, salicylic acids and amino acids. Aloe vera vitamins include vitamins A (beta-carotene), C and E, which are antioxidants and vitamin B12, folic acid, and choline. Aloe vera enzymes include aliiase, alkaline phosphatase, amylase, bradykinase, carboxypeptidase, catalase, cellulase, lipase, and peroxidase. Bradykinase helps to reduce excessive inflammation when applied to the skin topically, while others help in the breakdown of sugars and fats.
Aloe vera minerals include calcium, chromium, copper, selenium, magnesium, manganese, potassium, sodium and zinc. Aloe vera sugars include monosaccharides (glucose and fructose) and polysaccharides (glucomannans/polymannose). These are derived from the mucilage layer of the plant and are known as mucopolysaccharides. The most prominent monosaccharide is mannose-6-phosphate, and the most common polysaccharides are called glucomannans [beta-(1,4)-acetylated mannan]. Acemannan, a prominent glucomannan has also been found. A glycoprotein with antiallergic properties, called alprogen and novel anti-inflammatory compound, C-glucosyl chromone has been isolated from Aloe vera gel.
Aloe vera anthraquinones include phenolic compounds traditionally known as laxatives and Aloin and emodin act as analgesics, antibacterials and antivirals. Aloe vera fatty acids include 4 plant steroids; cholesterol, campesterol, β-sisosterol and lupeol. All these have anti-inflammatory action and lupeol also possesses antiseptic and analgesic properties. Aloe vera hormones include auxins and gibberellins that help in wound healing and have anti-inflammatory action. Aloe vera other potentially active constituents include 20 of the 22 human required amino acids and 7 of the 8 essential amino acids. It also contains salicylic acid that possesses anti-inflammatory and antibacterial properties. Lignin, an inert substance, when included in topical preparations, enhances penetrative effect of the other ingredients into the skin. Saponins that are the soapy substances form about 3% of the gel and have cleansing and antiseptic properties.
One example of the benefits of Aloe Vera is found in the use of Aloe Vera juice mixed with water and honey used as an effective antimalarial cure in Yemen. There are many other reported and studied uses and benefits throughout the world of one embodiment.
Some studies characterize the Aloe Vera phytochemical constituents of anthraquinones as one of the most important active ingredients of Aloe Vera. The antiplasmodial activity of Aloe Vera may be explained in the light of the presence of anthraquinones and other quinoid compounds which exert good activity against P. falciparum. The four main anthraquinones showing quite high medical values are acemannan, aloe-emodin, aloe bitter and aloe lectin of one embodiment.
Liposome Encapsulated Inflacin Compound:Inflacin provides its analgesic benefit when applying the topical cream to areas of the body affected by stiffness, soreness and pain. These include: hands, feet, knees and shoulders and muscles of the neck, arms, legs and back. Liposome encapsulated Inflacin in for example a topical cream delivers rapid absorption through the skin cells to deliver pain relief and increased mobility for example hand gripping within minutes of one embodiment.
Liposome Encapsulated CBD, Aloe Vera, and Inflacin Compounds:It should be understood that the selection of both Aloe Vera components and cannabis components can be formulated as any of the components alone or in various combinations of components from each group of Aloe Vera components and cannabis components. The products for oral sublingual ingestion and nasal spray, and suppository insertion and tampon vaginal insertion 630 or topical applications including underarm topical application 640 may be formulated for targeting specific medical benefits for specific conditions and symptoms. For example as shown in
A liposome delivery system may include products for oral sublingual ingestion and nasal spray, and suppository insertion and tampon vaginal insertion 630 or topical applications including underarm topical application 640. Liposome delivery system products for oral including sublingual ingestion and nasal spray may include at least one of a group beverages, flavored beverages, pills, capsules, tablets and sprays and for suppository insertion include rectal suppositories used by humans. Liposome delivery system products for topical applications including underarm topical application 640 include at least one of a group of forms including creams, gels, ointments, salves, sprays, powders, serums, liquids, toners, and oils for use in cosmetics, first aid, and sunscreens by humans.
A liposome delivery system in topical applications including underarm topical application 640 may be formulated with these combined Aloe Vera and cannabis components to target arthritic inflammation where a topical cream is formed for applying to a person's hands that are suffering from arthritis of one embodiment.
Liposome Attaching to Human Cell and Both Opening for Transfer of Aloe Vera and CBD into the Human Cell:
Mood/behavior 840 conditions are treated using a combination of CBC, CBD, CBG, CBN, and THC 850 for depression 860. CBD, CBG 852 is used to treat anxiety 862.
CBD, THC 854 helps control ADD/ADHD, stress 864, attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). The combination of CBD, CBG, and THC 856 is used to treat bipolar, OCD, PTSD 866, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) of one embodiment.
Other 870 conditions and symptoms include the use of CBD, THC 880 for treating asthma, fatigue, hypertension 890, and CBG, THC 881 for glaucoma 891. Another combination of CBD, THC, THCA 882 for treatment of HIV/Aids 892. Treatments with CBC, CBD, CBG, and THC 883 are beneficial for muscular dystrophy 893. The liposome cannabis product combination of components CBC, CBD, CBDA, CBG, THC, and THCA 884 is used for providing relief from cancer 894 and cancer treatment symptoms of one embodiment. The benefits are further described in
Neurological 940 conditions are treated using liposome combinations of cannabis product components. CBD, THC 950 is used to treat Tourette's 960 syndrome symptoms. CBD, CBN, THCA, THCV 951 help control epilepsy, seizures 961 onsets. CBCD, CBN, THC, THCA 952 is used to treat the symptoms of multiple sclerosis 962.
The combination of CBC, CBD, CBG, THC, and THCA 953 is used to treat Alzheimer's, Parkinson's 963. CBD, CBG, CBN, THC, THCA 954 reduces spasticity 964. CBC, CBD, CBG, CBN, THCV 955 benefit osteoporosis 965 effects. CBC, CBD, CBG, CBN, THC, THCA 956 is used to treat ALS 966, Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease of one embodiment.
Examples of Cannabinoid Component Product Benefits:Aloe vera 1210 has benefits that include antioxidant and antibacterial properties 1220, lowers the triglyceride levels among people with type 2 diabetes 1221, accelerates the healing of burns 1222, reduces dental plaque 1223, improve skin and prevent wrinkles 1224, lowers blood sugar levels in diabetics 1225, reduce hair loss 1226, relieve psoriatic arthritis symptoms 1230, treat acne lesions 1231, keeping skin hydrated and clear 1232, treat skin burns 1233, reduce itchiness and inflammation 1234, a pain reliever salicylic acid found in Aloe Vera 1235, treat hemorrhoids 1236, and anti-inflammatory properties 1237 of one embodiment.
Nano Sensors Suspended in an Encapsulation Media:Liposome Delivery System Cellular Transfer into a User's Skin:
The 3d depth camera 1420 is capturing images of wrinkles beginning to fade 1455. When the liposome released compounds are fully penetrating deeper into user's skin 1470 the user's forehead wrinkles are significantly lessened in prominence 1460. The 3d depth camera 1420 has been capturing images of the significantly faded wrinkles on the user's forehead 1485. The user's application of the topical cream of the liposome delivery system cellular transfer compounds has quickly and effectively reduced the user's forehead wrinkles of one embodiment.
Cellular Transfer Augmented Reality Application Previewing Treatment Potential Results:The foregoing has described the principles, embodiments and modes of operation of the present invention. However, the invention should not be construed as being limited to the particular embodiments discussed. The above described embodiments should be regarded as illustrative rather than restrictive, and it should be appreciated that variations may be made in those embodiments by workers skilled in the art without departing from the scope of the present invention as defined by the following claims.
Claims
1-20. (canceled)
21. A drug treatment assay system, comprising:
- a purification device configured for detecting and isolating live cancer cells from dead cancer cells and non-cancer cells of a patient biopsy sample;
- a testing device coupled to the purification device configured to infuse at least one drug treatment to the live cancer cells;
- an optical density device coupled to the testing device configured for measuring a rate of death of the live cancer cells at different intervals for a predetermined period of time after infusion of the at least one drug treatment;
- a processor coupled to the optical density device configured for analyzing measured rates of death of the live cancer cells; and
- at least one computer coupled to the processor configured for using analyzed rate of death results, specific patient genetic markers associated with cancer and drug resistance and allergies to generate and transmit clinician treatment recommendations for the patient's treatment based on the analyzed rate of death results of the live cancer cells testing.
22. The drug treatment assay system of claim 21, wherein the clinician treatment recommendations are used to assess anti-inflammatory therapies.
23. The drug treatment assay system of claim 21, wherein the clinician treatment recommendations are used to assess anti-immunological therapies.
24. The drug treatment assay system of claim 21, wherein the rate of death of the live cancer cells testing includes a spectrophotometric analysis at different intervals configured to collect optical density readings and/or cell count numbers for total testing times.
25. The drug treatment assay system of claim 21, wherein the processor analyzing the measured rates of death of the live cancer cells is configured for analyzing patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergy and in parallel assess where DNA mutations exists including in a tumor and bloodline mutations.
26. The drug treatment assay system of claim 21, wherein the testing device is configured to infuse at least one drug treatment including a single drug or a combination of drugs.
27. The drug treatment assay system of claim 21, wherein the optical density device is configured for measuring an increase of immune antigen stimulation to kill cancer cells and release of antigens to a patient's immune system.
28. An apparatus, comprising:
- a purification isolation device configured for isolating live cancer cells of a patient biopsy sample from non-cancer cells and dead cancer cells;
- a testing device coupled to the purification isolation device configured to infuse a drug or plurality of drugs to the live cancer cells;
- a digital processor coupled to the testing device configured to analyze testing results with patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergies;
- an optical density device coupled to the testing device configured for measuring rates of death of the live cancer cells;
- at least one correlation module coupled to the optical density device configured to correlate the rate of death of the live cancer cells testing with each drug infusion results;
- a digital processor coupled to the testing device configured to analyze testing results with patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergies; and
- at least one computer coupled to the at least one correlation module configured for generating clinician treatment recommendations to treat a patient with the drug infusion with a highest rate of death of the live cancer cells and transmitting the clinician treatment recommendations to the clinician for consideration for the patient's treatment.
29. The apparatus of claim 28, further comprising a network coupled with the at least one computer configured to automatically collect prior drug treatment outcomes data from patients and clinicians for analyzing effects on testing results.
30. The apparatus of claim 28, wherein the optical density device is configured to automatically repeat an optical density analysis of the rate of death of the live cancer cells at different intervals for a predetermined time.
31. The apparatus of claim 28, wherein a group of a single drug and a combination of drugs includes chemotherapy drugs, legal cannabinoids/CBD drugs, and immunotherapy drugs.
32. The apparatus of claim 28, wherein at least one correlation module is configured for identifying cannabinoid/CBD anti-tumor effects, immune-activity effects and enhancement of other drug anti-tumor effects.
33. The apparatus of claim 28, further comprising an optical microplate spectrophotometric reader coupled to the optical density device configured for measuring an increase of immune antigen stimulation treatment to kill live cancer cells and release of antigens to a patient's immune system.
34. A drug treatment evaluation method, comprising:
- detecting and isolating live cancer cells from dead cancer cells and non-cancer cells of a biopsy sample of a patient;
- infusing at least one drug treatment to the live cancer cells; measuring a rate of death of the live cancer cells at different intervals for a predetermined period of time after infusing the at least one drug treatment;
- analyzing the measured rate of death of the live cancer cells; and
- using the analyzed rate of death to generate clinician treatment recommendations for the patient's treatment based on the analyzed rate of death of the live cancer cells results.
35. The drug treatment evaluation method of claim 34, wherein measuring the rate of death of the live cancer cells includes collecting optical density readings and cell count numbers for total testing times.
36. The drug treatment evaluation method of claim 34, further comprising analyzing patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergy.
37. The drug treatment evaluation method of claim 34, further comprising collecting prior drug treatment outcomes data from patients and clinicians.
38. The drug treatment evaluation method of claim 34, wherein measuring the rate of death of the live cancer cells includes analyzing patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergies to assess the measured rate of death of the live cancer cells of drug treatments specific to that patient's current condition including genetics and prior treatment affects.
39. The drug treatment evaluation method of claim 34, wherein measuring a rate of death of the live cancer cells includes collecting optical density readings and cell count numbers for total testing times.
40. The drug treatment evaluation method of claim 34, wherein measuring the rate of death of the live cancer cells includes measuring a patient's at least one drug treated live cancer cells molecule release into a supernatant culture fluid including at least one from a group consisting of a protein, antigen, and cell component molecule.
Type: Application
Filed: Oct 7, 2022
Publication Date: Apr 20, 2023
Inventors: Nicolas DeFrank (Northridge, CA), Antonio DeFrank (Northridge, CA), Edmond A. DeFrank (Northridge, CA)
Application Number: 17/962,461